Stryker Corporation $SYK Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Stryker Corporation (NYSE:SYK) by 21.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,689,376 shares of the medical technology company’s stock after purchasing an additional 481,175 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Stryker were worth $846,723,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. New Mexico Educational Retirement Board boosted its position in shares of Stryker by 7.5% in the 2nd quarter. New Mexico Educational Retirement Board now owns 17,109 shares of the medical technology company’s stock worth $5,387,000 after buying an additional 1,200 shares in the last quarter. Mufg Securities Americas Inc. increased its holdings in Stryker by 9.0% during the 2nd quarter. Mufg Securities Americas Inc. now owns 10,392 shares of the medical technology company’s stock valued at $3,272,000 after acquiring an additional 862 shares in the last quarter. Van ECK Associates Corp raised its position in Stryker by 7.6% during the second quarter. Van ECK Associates Corp now owns 22,011 shares of the medical technology company’s stock worth $6,930,000 after acquiring an additional 1,555 shares during the last quarter. Ferguson Wellman Capital Management Inc. lifted its holdings in shares of Stryker by 1.2% in the second quarter. Ferguson Wellman Capital Management Inc. now owns 186,935 shares of the medical technology company’s stock valued at $58,855,000 after purchasing an additional 2,180 shares in the last quarter. Finally, Roffman Miller Associates Inc. PA lifted its holdings in shares of Stryker by 1.0% in the second quarter. Roffman Miller Associates Inc. PA now owns 127,268 shares of the medical technology company’s stock valued at $40,069,000 after purchasing an additional 1,246 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. This represents a 2.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dylan Bram Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Stryker Stock Up 2.9%

Shares of NYSE:SYK opened at $331.32 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a market cap of $127.08 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 2.11 and a beta of 0.76. The stock’s 50-day moving average price is $329.10 and its two-hundred day moving average price is $331.47. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on SYK shares. Royal Bank Of Canada lowered their target price on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. JPMorgan Chase & Co. cut their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. BTIG Research reduced their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Leerink Partners decreased their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Finally, Barclays dropped their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.